Antigen-Presenting Cells 8015 (Provenge®) in Patients with Androgen-Dependent, Biochemically Relapsed Prostate Cancer

Therapy was well tolerated. APC8015 as single-agent immunotherapy for patients with ADPC and biochemical progression did not result in ≥ 50% decrease in PSA from baseline levels but did appear to modulate PSADT in some patients. Further manipulations of host immunity may be required to achieve a significant antitumor effect.